A newly described clinical strategy from Texas Children's Hospital and Baylor College of Medicine aims to shorten the diagnostic delay for biliary atresia (BA), a rare infant liver disease that can rapidly progress to irreversible injury. The approach, published in World Journal of Pediatric Surgery (DOI: 10.1136/wjps-2025-001142), pairs direct or conjugated bilirubin (DB/Bc) measurements with a feeding abdominal ultrasound exam to identify infants needing urgent evaluation while reducing unnecessary invasive testing.
Biliary atresia, thought to begin before birth when extrahepatic bile ducts fail to form properly, leads to bile accumulation and progressive liver injury. Early treatment with Kasai portoenterostomy (KP) before 30–45 days of life offers the best chance of delaying or avoiding liver transplantation, yet diagnosis often occurs after 60 days. The disease is difficult to detect because jaundice can mimic common newborn conditions, and pale stools may not appear immediately.
The proposed pathway begins with DB/Bc testing in the newborn nursery and early outpatient visits. Evidence suggests that DB/Bc levels can be elevated within the first 24–48 hours of life in infants with BA, before other clinical signs emerge. Primary care providers are guided to retest at 2–4 weeks for infants with persistent jaundice, pale stools, or prior high DB/Bc, aligning with American Academy of Pediatrics recommendations. For infants with elevated DB/Bc, a feeding ultrasound exam follows. Instead of requiring fasting, the infant feeds before or during imaging, making the duct at the hilum (DaH) easier to visualize. The exam also measures maximum echogenicity (MxE) near the right portal vein. An MxE greater than 4.0 mm or an absent DaH raises concern for BA and may prompt definitive evaluation, while other findings support continued outpatient assessment.
The authors emphasize that the strategy is designed to make early BA evaluation more actionable for the entire care team, from nursery providers and primary care physicians to radiologists, hepatologists, and surgeons. The goal is not to replace specialist judgment but to provide clearer signals when time is critical. By sharing the pathway, the researchers hope other centers will provide feedback, test the approach in diverse settings, and adapt useful components into their own workflows.
The potential implications are broad. Universal newborn DB/Bc screening could reduce diagnostic delays and address disparities by identifying risk before visual signs are missed. The feeding ultrasound approach may make follow-up less burdensome by avoiding fasting and potentially reducing reliance on tests requiring anesthesia or invasive procedures. For families, earlier detection could mean faster treatment decisions and a better chance of preserving the native liver. Future studies will need to evaluate implementation, cost-effectiveness, and performance across multiple centers and healthcare systems.
